OJEMD  Vol.3 No.3 , July 2013
Percutaneous Angioplasty in Diabetic Patients with Critical Limb Ischemia and Chronic Kidney Disease
Abstract: Introduction: Diabetes and Chronic Kidney Disease (CKD) are two strong risk factors for peripheral arterial disease (PAD) and Critical Limb Ischemia (CLI). Further renal insufficiency increases the risk of non healing wounds and major amputation. Primary amputation rates of 22% to 44% have been reported for ischaemic foot lesion in End-Stage Renal Disease (ESRD) patients. In our study we evaluated the outcomes after Percutaneus Transluminal Angioplasty (PTA) in diabetic patient in relation to different CKD classes. Materials and Methods: We studied a group of 456 diabetic patients with PAD complicated by foot lesion who underwent PTA because of a CLI. According to the estimated Glomerular Filtration Rate (eGFR mL/min/1.73 m2) we divided the patients into five CKD groups: group 1 eGFR > 90, group 2 eGFR 90 - 60 (n = 160), group 3 eGFR 60 - 30 (n = 152), group 4 eGFR 30 -15 (n = 34) and group 5 < 15 or in ESRD) (n = 60). The following outcomes were recorded: alive without major amputation, alive with major amputation and death. The follow-up was 16.7 ± 14.3 months. Results: Alive without major amputation, alive with major amputation and death were respectively: for group 1 (77.8%, 11.1%, 11.1%), for group 2 (74.4%, 12.5%, 13.1%), for group 3 (80.3%, 11.2%, 8.5%), for group 4 (82.3%, 8.8%, 8.8%). They were 60%, 18.3%, 21.7% for group 5 significantly different from the other CKD groups (χ2 = 0.0175). Our analysis did not highlight any relationship between eGFR and outcomes and eGFR did not show any significant difference according to the different outcomes, and were respectively 60.2 ± 1.3, 61.8 ± 3.4, 63.8 ± 3.5 (P = ns). Conclusion: The outcomes were similar for groups 1-4 and therefore, according to our data, they seemed not to be influenced by the decline of GFR. Outcomes worse significantly in group 5, but this group included only patients with ESRD in dialysis treatment. Although the outcomes after PTA in group 5 was significantly worse than the other groups, still a 60% limb salvage rate was obtained with PTA also in these very fragile patients. PTA was much less aggressive than by-pass and PTA was the only method used to treat CLI in our patients. This could explain why we recorded similar outcomes in all groups despite the decline of GFR that, generally speaking, mirrors a worsening of the general clinical conditions. Worse outcomes were recorded only in group 5 and in this group dialysis by itself might be responsible of the different outcomes.
Cite this paper: L. Giurato, R. Gandini, M. Meloni, E. Pampana, V. Ruotolo, V. Izzo, S. Fabiano, C. Giudice and L. Uccioli, "Percutaneous Angioplasty in Diabetic Patients with Critical Limb Ischemia and Chronic Kidney Disease," Open Journal of Endocrine and Metabolic Diseases, Vol. 3 No. 3, 2013, pp. 208-212. doi: 10.4236/ojemd.2013.33028.

[1]   L. Norgren, W. R. Hiatt, J. A. Dormandy, M. R. Nehler, K. A. Harris and F. G. Fowkes and TASC II Working Group, “Intersociety Consensus for the Management of Peripheral Arterial Disease (TASC II),” European Journal of Vascular and Endovascular Surgery, Vol. 33, Supplement 1, 2007, pp. S1-S75. doi:10.1016/j.ejvs.2006.09.024

[2]   L. Prompers, N. Schaper, J. Apelqvist, M. Edmonds, E. Jude and D. Mauricio, “Prediction of Outcome in Individuals with Diabetic Foot Ulcers: Focus on the Differences between Individuals with and without Peripheral Arterial Disease. The EURODIALE Study,” Diabetologia, Vol. 51, No. 5, 2008, pp. 747-755. doi:10.1007/s00125-008-0940-0

[3]   M. A. Gershater, M. Londahl, P. Nyberg, J. Larsson, J. Thorne and M. Eneroth, “Complexity of Factors Related to Outcome of Neuropathic and Neuroischaemic/Ischaemic Diabetic Foot Ulcers: A Cohort Study,” Diabetologia, Vol. 52, No. 3, 2009, pp. 398-407. doi:10.1007/s00125-008-1226-2

[4]   F. L. Game, S. Y. Chipchase, R. Hubbard, R. P. Burden and W. J. Jeffcoate, “Temporal Association between the Incidence of Foot Ulceration and the Start of Dialysis in Diabetes Mellitus,” Nephrology Dialysis Transplantation, Vol. 21, No. 11, 2006, pp. 3207-3210. doi:10.1093/ndt/gfl427

[5]   M. Albers, M. Romiti, C. A. Braganca Pereira, R. L. A. Fonseca and M. Da Silva Junior, “A Metaanalysis of Infrainguinal Arterial Reconstruction in Patients with ESRD,” European Journal of Vascular and Endovascular Surgery, Vol. 22, No. 4, 2001, pp. 294-300. doi:10.1053/ejvs.2001.1469

[6]   F. Pomposelli, “Arterial Imaging in Patients with Lower Extremity Ischemia and Diabetes Mellitus,” Journal of Vascular Surgery, Vol. 52, Supplement 3, 2010, pp. 81S-91S. doi:10.1016/j.jvs.2010.06.013

[7]   M. Heikkinen, M. Salmenpera, A. Lepantalo and M. Lepantalo, “Diabetes Care for Patients with Peripheral Arterial Disease,” European Journal of Vascular and Endovascular Surgery, Vol. 33, No. 5, 2007, pp. 583-591. doi:10.1016/j.ejvs.2007.01.012

[8]   M. R. Prince, H. Zhang, M. Morris, J. L. MacGregor, M. E. Grossman and J. Silberzweig, “Incidence of Nephrogenic Systemic Fibrosis at Two Largemedical Centers,” Radiology, Vol. 248, No. 3, 2008, pp. 807-816. doi:10.1148/radiol.2483071863

[9]   C. Rydahl, H. S. Thomsen and P. Marckmann, “High Prevalence of Nephrogenic Systemic Fibrosis in Chronic Renal Failure Patients Exposed to Gadodiamide, a Gadolinium-Containing Magnetic Resonance Contrast Agent,” Investigative Radiology, Vol. 43, No. 2, 2008, pp. 141-144.

[10]   R. Wertman, E. Altun, D. R. Martin, D. G. Mitchell, J. R. Leyendecker and R. B. O’Malley, “Risk of Nephrogenic Systemic Fibrosis: Evaluation of Gadolinium Chelate Contrast Agents at Four American Universities,” Radiology, Vol. 248, No. 3, 2008, pp. 799-806. doi:10.1148/radiol.2483072093

[11]   R. J. Hinchliffe, G. Andros, J. Apelqvist, K. Bakker, S. Friederichs and J. Lammer, “A Systematic Review of the Effectiveness of Revascularization of the Ulcerated Foot in Patients with Diabetes and Peripheral Arterial Disease,” Diabetes/Metabolism Research and Reviews, Vol. 28, Supplement 1, 2012, pp. 179-217. doi:10.1002/dmrr.2249

[12]   C. D. Owens, K. J. Ho, S. Kim, A. Schanzer, J. Lin and E. Matros, “Refinement of Survival Prediction in Patients Undergoing Lower Extremity Bypass Surgery: Stratification by Chronic Kidney Disease Classification,” Journal of Vascular Surgery, Vol. 45, No. 5, 2007, pp. 944-952. doi:10.1016/j.jvs.2007.01.025

[13]   S. Rajagopalan, S. Dellegrottaglie, A. L. Furniss, B. W. Gillespie, S. Satayathum and N. Lameire, “Peripheral Arterial Disease in Patients with End-Stage Renal Disease: Observation from the Dialysis Outcomes and Practice Patterns Study (DOPPS),” Circulation, Vol. 114, No. 18, 2006, pp. 1914-1922. doi:10.1161/CIRCULATIONAHA.105.607390

[14]   S. Fishbane, S. Youn, E. Flaster, G. Adam and J. K. Maesaka, “Ankle-Arm Blood Pressure Index as a Predictor of Mortality in Hemodialysis Patients,” American Journal of Kidney Diseases, Vol. 27, No. 5, 1996, pp. 668-672. doi:10.1016/S0272-6386(96)90101-8

[15]   A. O’Hare and K. Johansen, “Lower-Extremity Peripheral Arterial Disease among Patients with End-Stage Renal Disease,” Journal of the American Society of Nephrology, Vol. 12, No. 12, 2001, pp. 2838-2847.

[16]   A. O’Hare, D. V. Glidden, C. S. Fox and C. Hsu, “High Prevalence of Peripheral Arterial Disease in Person with Renal Insufficiency. Results from the National Health and Nutritional Examination Survey. 1999-2000,” Circulation, Vol. 109, No. 3, 2004, pp. 320-323. doi:10.1161/01.CIR.0000114519.75433.DD

[17]   K. Wattanakit, A. R. Folsom, E. Selvin, J. Coresh, A. T. Hirsch and B. D. Weatherley, “Kidney Function and Risk of Peripheral Arterial Disease: Results from the Atherosclerosis Risk in Communities (ARIC) Study,” Journal of the American Society of Nephrology, Vol. 18, No. 2, 2007, pp. 629-636. doi:10.1681/ASN.2005111204

[18]   B. G. Jaar, L. C. Plantinga, B. C. Astor, N. E. Fink, C. Longenecker and R. P. Tracy, “Novel and Traditional Cardiovascular Risk Factors for Peripheral Arterial Disease in Incident-Dyalisis Patients,” Advances in Chronic Kidney Disease, Vol. 14, No. 3, 2007, pp. 304-313. doi:10.1053/j.ackd.2007.04.005

[19]   R. N. Foley, P. S. Parfrey, J. D. Harnett, G. M. Kent, L. Hu and R. O’Dea, “Hypocalcemia, Morbidity, and Mortality in End-Stage Renal Disease,” American Journal of Nephrology, Vol. 16, No. 5, 1996, pp. 386-393. doi:10.1159/000169030

[20]   B. F. Culleton, M. G. Larson, P. W. F. Wilson, J. C. Evans, P. S. Parfrey and D. Levy “Cardiovascular Disease and Mortality in a Community-Based Cohort with Mild Renal Insufficiency,” Kidney International, Vol. 56, No. 6, 1999, pp. 2214-2219. doi:10.1046/j.1523-1755.1999.00773.x

[21]   A. S. Go, G. M. Chertow, D. Fan, C. E. McCullock and C. Y. Hsu, “Chronic Kidney Disease and the Risk of Death, Cardiovascular Events, and Hospitalization,” The New England Journal of Medicine, Vol. 351, No. 13, 2004, pp. 1296-1305. doi:10.1056/NEJMoa041031

[22]   M. Venermo, F. Biancari, E. Arvela, M. Korhonen, M. Soderstrom and K. Halmesmaki, “The Role of Chronic Kidney Disease as a Predictor of Outcome after Revascularisation of the Ulcerated Diabetic Foot,” Diabetologia, Vol. 54, No. 12, 2011, pp. 2971-2977. doi:10.1007/s00125-011-2279-1